Strand asymmetry of CpG transitions as indicator of G 1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells
- 29 September 1998
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (20) , 11927-11932
- https://doi.org/10.1073/pnas.95.20.11927
Abstract
In dividing cells, expression of mutations is DNA strand symmetric. Of all mutations originating de novo in nondividing cells, only those in the transcribed (noncoding) strand are immediately expressed in mRNA and protein. In contrast, any new mutation in the nontranscribed (coding) strand remains unexpressed until the cells enter S phase and begin proliferation. This previously unrecognized difference enables us to examine the cell cycle-dependent origin of multiple tumorigenic mutations in stem cells. The human p53 gene, which acts as a gatekeeper in the control of G1 to S phase transition, was chosen for the analysis. Of all multiple mutations contained in p53 databases, we have tested in detail CpG transitions. Three features of CpG sites dictate this choice: C → T transitions at methylated mCpG are the direct product of mC deamination and are replication-independent; it is easy to identify the strand bearing a primary mC → T event because C → T on the transcribed strand appears as G → A on the nontranscribed strand; and CpG transitions are the most frequent (as both singular and multiple occurrences) tumor-related p53 mutations. The origin of double nonsilent CpG transitions in nondividing cells predicts a significant excess of the heterostrand (C → T, G → A) doublets over the homostrand (C → T, C → T and G → A, G → A) doublets. For p53, we found such an excess. Based on this result, along with the results of three other tests reported here, we conclude that the majority of multiple p53 mutations from human tumors occurred in quiescent stem cells.Keywords
This publication has 39 references indexed in Scilit:
- Silent and multiple mutations in p53 and the question of the hypermutability of tumors [published erratum appears in Carcinogenesis 1998 Jan;19(1):237]Carcinogenesis: Integrative Cancer Research, 1997
- The Rate of CpG Mutation inAluRepetitive Elements within the p53 Tumor Suppressor Gene in the Primate GermlineJournal of Molecular Biology, 1996
- Multiple mutations in human cancersMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996
- Life (and death) in a malignant tumourNature, 1996
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Slow Repair of Pyrimidine Dimers at p53 Mutation Hotspots in Skin CancerScience, 1994
- 5-Methylcytosine as an Endogenous Mutagen in the Human LDL Receptor and p53 GenesScience, 1990
- A Method For Measuring the Generation Time and Length of Dna Synthesizing Phase of Clonogenic Cells In A Heterogenous PopulationCell Proliferation, 1981
- The Clonal Evolution of Tumor Cell PopulationsScience, 1976
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971